MarketLens
Sign Up

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

8 months ago
SHARE THIS ON:

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?

Bristol Myers Squibb (BMY) is the subject of a Zacks value-focused article questioning whether investors are undervaluing the stock. The piece highlights Zacks Rank and value, growth, and momentum tre...
Stock News•1 months ago

Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?

Bristol Myers Squibb's growth portfolio is gaining ground as newer drugs offset mature-product declines, reshaping its revenue mix. The shift could stabilize overall sales if new launches keep scaling...
Stock News•1 months ago

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Bristol Myers Squibb faces Eliquis patent expiry in 2028, a key revenue risk. The company is advancing new drugs and pipeline candidates to offset projected losses, though near-term financial impact r...

Breaking News

View All →

Top Headlines

View More →
Stock News•25 minutes ago

SK Hynix third-quarter profit sharply beats estimates on AI memory boost

Stock News•1 hour ago

History Says the Stock Market's Best 6 Months Start Nov. 1. Here's How Often They've Paid Off Since 1950.

Stock News•2 hours ago

AI Cash Kings: 3 Top Chip Stocks Primed For More Explosive Growth

Stock News•2 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alphabet Inc. of Class Action Lawsuit and Upcoming Deadlines – GOOG

Stock News•2 hours ago

Nvidia's New $3 Billion AI Bet Is on One of Its Own Customers